Omnicef

Common Uses

Omnicef is prescribed to treat infections caused by susceptible bacteria. It is commonly used for the following conditions:

• Respiratory tract infections: This includes community-acquired pneumonia and flare-ups of chronic bronchitis.
• Ear, nose, and throat infections: It is used to treat middle ear infections (otitis media) in children, as well as sinus infections (sinusitis), tonsillitis, and strep throat (pharyngitis).
• Skin infections: It is used for certain types of uncomplicated skin and skin structure infections.

Important Considerations

Omnicef is only effective against bacterial infections. It will not work for viral infections, such as the common cold or the flu. Using antibiotics when they are not needed increases the risk of developing an infection later that resists antibiotic treatment.

Mechanism of Action

Omnicef belongs to a class of medications known as cephalosporin antibiotics. It works by interfering with the process bacteria use to create their cell walls.

Bacteria need a strong, rigid outer wall to protect themselves and maintain their structure. Omnicef binds to specific proteins within the bacterial cell, preventing the bacteria from properly forming these walls. Without a stable cell wall, the bacteria eventually burst or die, which stops the infection from spreading.

Targeting Bacteria

This medication is designed to target bacterial cells specifically. Because human cells do not have cell walls, the drug does not affect the body's own cells in the same way. It is important to note that Omnicef only works against bacterial infections; it is not effective against viral infections, such as the common cold or the flu.

Common Side Effects

• Diarrhea
• Nausea
• Headache
• Abdominal pain
• Vaginal itching or discharge
• Diaper rash in infants and young children

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Severe stomach cramps or watery or bloody diarrhea
• Signs of an allergic reaction, such as hives, swelling of the face or throat, or difficulty breathing
• Fever, sore throat, or body aches
• A red or purple skin rash that blisters or peels
• Yellowing of the eyes or skin (jaundice)
• Dark-colored urine or changes in the amount of urine
• Seizures

Note on stool color: If you take Omnicef while also taking iron supplements or multivitamins containing iron, your stools may turn a reddish color. This is a known interaction and is typically not harmful.

Allergic Reactions

Before starting treatment, it is important to determine if there is a history of hypersensitivity to cefdinir, other cephalosporins, penicillins, or other drugs. There is a risk of cross-sensitivity among beta-lactam antibiotics. If an allergic reaction occurs, the medication should be discontinued immediately.

Clostridioides Difficile-Associated Diarrhea (CDAD)

Nearly all antibacterial agents, including Omnicef, can cause Clostridioides difficile-associated diarrhea. This condition can range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to the overgrowth of C. difficile. If diarrhea occurs during or after treatment, medical evaluation is necessary.

Drug Resistance

Using Omnicef in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of developing drug-resistant bacteria.

Patients with Kidney Problems

In patients with transient or persistent renal insufficiency, the total daily dose may need to be reduced. Cephalosporins as a class have been linked to seizures, particularly in patients with kidney impairment who did not receive a dose adjustment.

Interactions and Observations

• Iron and Antacids: Taking Omnicef with iron supplements or antacids containing magnesium or aluminum can significantly decrease the absorption of the drug. These should be taken at least two hours apart from the antibiotic dose.
• Red Stools: Patients taking iron-containing products (including infant formula) may notice reddish stools. This is due to the formation of a non-absorbable complex in the gastrointestinal tract and is generally not a cause for concern.

Pregnancy

There are no adequate and well-controlled studies of Omnicef in pregnant women. Animal reproduction studies using doses many times higher than the human dose have not shown evidence of harm to the fetus. However, because animal studies are not always predictive of human response, this medication should be used during pregnancy only if it is clearly needed.

Breastfeeding

Following a single 600 mg dose, Omnicef was not detected in human breast milk. It is generally considered unlikely to cause harm to a nursing infant. However, you should inform your doctor if you are breastfeeding or plan to breastfeed while taking this medication to ensure it is the most appropriate option for you and your baby.

Available Dosage Forms

Omnicef (cefdinir) is provided in two primary oral formulations:

• Capsules: These are oral pills typically used for adults and older children.
• Powder for Oral Suspension: This is a powder that is mixed with water by a pharmacist to create a liquid medication. It is commonly used for pediatric patients or individuals who have difficulty swallowing capsules.

The oral suspension is available in different concentrations to allow for accurate dosing based on the patient's weight and the specific type of infection being treated.

FDA Approval and Indications

Omnicef, which contains the active ingredient cefdinir, was first approved by the U.S. Food and Drug Administration (FDA) in 1997. It is a third-generation cephalosporin antibiotic indicated for the treatment of mild to moderate infections caused by susceptible bacteria. The FDA has approved its use for the following conditions:

• Community-acquired pneumonia
• Acute exacerbations of chronic bronchitis
• Acute maxillary sinusitis
• Pharyngitis and tonsillitis
• Uncomplicated skin and skin structure infections
• Acute bacterial otitis media (middle ear infections) in children

Regulatory Status and Safety

Omnicef is classified as a prescription-only medication. It does not currently have a Boxed Warning, which is the FDA's most serious warning for high-risk medications, nor does it require a Risk Evaluation and Mitigation Strategy (REMS) program. To reduce the development of drug-resistant bacteria and maintain the effectiveness of the drug, the FDA requires labeling to specify that Omnicef should only be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Generic Availability

The FDA has approved multiple generic versions of cefdinir in various forms, including oral capsules and liquid suspensions. Generic versions are required to meet the same rigorous standards for safety, efficacy, and quality as the original brand-name product.

Generic Availability

Omnicef is available as a generic medication called cefdinir. Generic versions contain the same active ingredients as the brand-name drug but are typically available at a lower cost. Most insurance plans cover the generic version of this antibiotic.

Factors Influencing Cost

Several factors can affect the final price of the medication:

• Dosage Form: Cefdinir is available as capsules and as a liquid oral suspension. The price may differ between these two forms.
• Treatment Duration: The total number of capsules or the volume of liquid required for the full course of treatment will impact the total cost.
• Pharmacy Choice: Retail prices can vary between different pharmacies and mail-order services.

Insurance and Assistance

Most health insurance providers, including Medicare and Medicaid, provide coverage for generic cefdinir. Brand-name Omnicef may be subject to higher co-pays or may not be covered if a generic equivalent is available. Patients are encouraged to check their specific plan's formulary or speak with a pharmacist to understand their out-of-pocket costs.